Trade Report: Today, Intercept Pharmaceuticals’ (ICPT) “Buy” Rating Reaffirm at JMP Securities

Today, Intercept Pharmaceuticals’ (ICPT) “Buy” Rating Reaffirm at JMP Securities

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “buy” rating reiterated by investment analysts at JMP Securities in a research note issued to investors on Sunday.

Several other equities research analysts have also weighed in on the company. Wedbush restated an “outperform” rating and set a $239.00 price target on shares of Intercept Pharmaceuticals in a research report on Monday, July 25th. Credit Suisse Group AG restated a “buy” rating and set a $200.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Vetr lowered Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $81.50 price target on the stock. in a research report on Monday, August 8th. Oppenheimer Holdings Inc. dropped their price target on Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating on the stock in a research report on Friday, August 5th. Finally, Cantor Fitzgerald restated a “sell” rating and set a $60.00 price target on shares of Intercept Pharmaceuticals in a research report on Monday, August 8th. Five research analysts have rated the stock with a sell rating, four have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and an average target price of $177.07.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 1.37% during midday trading on Friday, hitting $115.84. The stock had a trading volume of 213,503 shares. Intercept Pharmaceuticals has a 12 month low of $89.76 and a 12 month high of $186.87. The stock’s market cap is $2873.87 billion. The stock’s 50-day moving average is $124.14 and its 200-day moving average is $145.79.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.82) by $0.23. Intercept Pharmaceuticals had a negative return on equity of 66.97% and a negative net margin of 3,287.95%. The firm had revenue of $4.70 million for the quarter, compared to analysts’ expectations of $4.77 million. During the same period in the previous year, the firm earned ($2.10) earnings per share. The business’s revenue was up 1051.1% compared to the same quarter last year. Equities analysts anticipate that Intercept Pharmaceuticals will post ($15.63) EPS for the current year.

In other Intercept Pharmaceuticals news, CMO David Shapiro sold 3,545 shares of the company’s stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $165.08, for a total value of $585,208.60. Following the completion of the sale, the chief marketing officer now owns 45,732 shares in the company, valued at $7,549,438.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Mark Pruzanski sold 35,000 shares of the company’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $165.00, for a total value of $5,775,000.00. Following the completion of the transaction, the chief executive officer now directly owns 579,314 shares of the company’s stock, valued at approximately $95,586,810. The disclosure for this sale can be found here. 9.20% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. raised its position in Intercept Pharmaceuticals by 10.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 52,058 shares of the biopharmaceutical company’s stock worth $7,775,000 after buying an additional 4,776 shares during the period. CenturyLink Investment Management Co raised its position in Intercept Pharmaceuticals by 94.6% in the fourth quarter. CenturyLink Investment Management Co now owns 2,092 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 1,017 shares during the period. BlackRock Fund Advisors raised its position in Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock worth $60,030,000 after buying an additional 31,289 shares during the period. Wells Fargo & Company MN raised its position in Intercept Pharmaceuticals by 15.8% in the fourth quarter. Wells Fargo & Company MN now owns 38,324 shares of the biopharmaceutical company’s stock worth $5,724,000 after buying an additional 5,239 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in Intercept Pharmaceuticals by 1.7% in the fourth quarter. DekaBank Deutsche Girozentrale now owns 12,310 shares of the biopharmaceutical company’s stock worth $1,847,000 after buying an additional 200 shares during the period. 81.54% of the stock is owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

Related posts

Leave a Comment